-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Yellow fever (YF) is a viral disease found in tropical regions of Africa and the Americas.
the disease mainly affects humans and monkeys and is transmitted through the bite of the Aedes aegypti mosquito.
the disease can lead to highly destructive outbreaks that can be prevented and controlled through mass vaccination campaigns. The initial symptoms of
disease usually appear 3-6 days after infection. the first stage of
was characterized by fever, muscle pain, headache, chills, and after 3-4 days, most patients improved and their symptoms disappeared.
However, in a few cases, the disease entered the "toxicity" phase, and about 50 per cent of patients who entered the toxic phase died within 10-14 days.
Tychan, a Singapore-based biotech company, announced today that a study in the New England Journal of Medicine (NEJM) demonstrated the safety and effectiveness of monoclonal antibody TY014 in the treatment of yellow fever (YF). Professor Ram Sasisekharan, founder of
Tychan, said: "It is imperative to quickly find a cure for yellow fever, as outbreaks of infectious diseases will become more frequent and will have significant social and economic impacts.
COVID-19 pandemic is an example." The phase Ia study of
evaluated the safety, tolerance and pharmacokinetics of monoclonal antibody TY014 in healthy volunteers, consisted of five random queues, double-blinddesigned the first dose cohort (0.5 mg / kg) and designed an open label scheme.
the remaining four dosing groups are 2, 5, 10 and 20 mg / kg.
22 volunteers received TY014 and five received placebos.
this phase of the study reached the endpoint of safety and efficacy: 100% of the subjects inthesion were negative for viral blood disorder within 48 hours of infusion.
.